$QTTB SEC Filings

Filed On	Filing
14 Oct 2026	Form 4: Morrison Jodie Pope, Director Sold 3,221 shares ($26.8K)
14 Oct 2026	Form 4: Violette Shelia M., Chief Scientific Officer Sold 917 shares ($7.63K)
14 Oct 2026	Form 4: Kalowski Lee, CFO and President Sold 1,301 shares ($10.8K)
09 Oct 2026	SCHEDULE 13G
30 Sep 2026	8-K: Regulation FD Disclosure; Other Events Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
14 Sep 2026	8-K: Regulation FD Disclosure; Other Events Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
27 Aug 2026	Form 4: Morrison Jodie Pope, Director Sold 9,845 shares ($163K)
27 Aug 2026	Form 4: Kalowski Lee, CFO and President Sold 3,972 shares ($65.8K)
27 Aug 2026	Form 4: Violette Shelia M., Chief Scientific Officer Sold 2,798 shares ($46.3K)
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G/A
05 Aug 2026	10-Q
05 Aug 2026	8-K: Results of Operations and Financial Condition
31 Jul 2026	SCHEDULE 13G/A
28 Jul 2026	EFFECT
28 Jul 2026	424B3
21 Jul 2026	Form 4/A: Tzianabos Arthur, Director Granted 10,826 Stock Option (Right to Buy)
21 Jul 2026	Form 4/A: Lundberg Sven Ante, Director Granted 10,826 Stock Option (Right to Buy)
21 Jul 2026	Form 4/A: Laporte Kathleen, Director Granted 10,826 Stock Option (Right to Buy)
21 Jul 2026	Form 4/A: Iwicki Mark T, Director Granted 10,826 Stock Option (Right to Buy)

Comments